|

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

RECRUITINGPhase 4Sponsored by Herlev and Gentofte Hospital
Actively Recruiting
PhasePhase 4
SponsorHerlev and Gentofte Hospital
Started2024-10-10
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06642272

Summary

The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults aged 18 years or more

Exclusion Criteria:

* Incapabability of giving informed consent
* Withdrawal of informed consent

Conditions5

Chronic Kidney DiseasesDiabetesDiabetes Mellitus, Type 2Heart DiseaseHeart Failure

Browse More Trials

Heart Disease trialsDiabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.